Philadelphia Financial Management Of San Francisco Lifted James Riv Group LTD (JRVR) Holding By $1.97 Million; Agios Pharmaceuticals, Inc. (AGIO) Had 12 Bullish Analysts

December 6, 2017 - By Richard Conner

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 8 by Cowen & Co. The rating was downgraded by Janney Capital on Monday, June 26 to “Neutral”. The firm earned “Buy” rating on Monday, June 5 by Canaccord Genuity. Leerink Swann upgraded the stock to “Outperform” rating in Wednesday, August 2 report. The company was maintained on Wednesday, May 18 by Credit Suisse. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Buy” rating given on Wednesday, November 1 by RBC Capital Markets. As per Tuesday, June 6, the company rating was maintained by Cowen & Co. TH Capital maintained the shares of AGIO in report on Monday, November 9 with “Neutral” rating. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Outperform” rating given on Tuesday, January 17 by Oppenheimer. As per Tuesday, August 8, the company rating was maintained by Oppenheimer. See Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) latest ratings:

19/11/2017 Broker: SunTrust Rating: Buy New Target: $80.0 Maintain
01/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $80.0 Maintain
02/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: $61 New Target: $66 Maintain
03/10/2017 Broker: SunTrust Rating: Buy New Target: $80.0 Maintain
18/09/2017 Broker: J.P. Morgan Rating: Buy New Target: $76.0 Maintain
15/09/2017 Broker: Needham Rating: Buy New Target: $72.0 Maintain
15/09/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $78 Initiates Coverage On
08/08/2017 Broker: SunTrust Rating: Buy New Target: $80.0000
08/08/2017 Broker: Cowen & Co Rating: Buy Maintain
08/08/2017 Broker: Oppenheimer Rating: Buy New Target: $83.0000 Maintain

Philadelphia Financial Management Of San Francisco Llc increased James Riv Group Ltd (JRVR) stake by 12.03% reported in 2017Q2 SEC filing. Philadelphia Financial Management Of San Francisco Llc acquired 50,423 shares as James Riv Group Ltd (JRVR)’s stock declined 8.95%. The Philadelphia Financial Management Of San Francisco Llc holds 469,401 shares with $18.65M value, up from 418,978 last quarter. James Riv Group Ltd now has $1.19B valuation. It closed at $40.15 lastly. It is down 33.65% since December 6, 2016 and is uptrending. It has outperformed by 16.95% the S&P500.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $2.85 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Since June 13, 2017, it had 0 insider buys, and 1 sale for $101,730 activity. 2,000 shares valued at $101,730 were sold by Cantley Lewis Clayton Jr. on Tuesday, June 13.

The stock decreased 4.65% or $2.85 during the last trading session, reaching $58.48. About 204,950 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since December 6, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Investors sentiment increased to 2.04 in Q2 2017. Its up 0.71, from 1.33 in 2017Q1. It is positive, as 14 investors sold Agios Pharmaceuticals, Inc. shares while 32 reduced holdings. 22 funds opened positions while 72 raised stakes. 44.72 million shares or 14.71% more from 38.98 million shares in 2017Q1 were reported. Sei Investments Co reported 23 shares stake. Citadel Advsr Ltd Liability Co has 155,353 shares for 0.01% of their portfolio. 157 were accumulated by Valley Advisers. Bnp Paribas Arbitrage Sa invested in 0% or 13,575 shares. Cap Invsts reported 663,000 shares or 0.01% of all its holdings. Alliancebernstein Ltd Partnership owns 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 21,742 shares. Capital Ca has 340,337 shares. Profund Advsr Limited Liability reported 15,971 shares stake. Clearbridge Invests Ltd Liability holds 0.08% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 1.53M shares. Legal General Gru Public Ltd Com stated it has 12,517 shares or 0% of all its holdings. Quantitative Mgmt Ltd Liability Com has invested 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Bb Biotech Ag has invested 4.51% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Paradigm Asset Mgmt Communications stated it has 3,900 shares. Rhumbline Advisers owns 46,282 shares or 0.01% of their US portfolio. Pnc Services Grp has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com